New drug combo aims to make stem cell transplants safer for blood cancer patients

NCT ID NCT03314974

Recruiting now Disease control Sponsor: Masonic Cancer Center, University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of three drugs (cyclophosphamide, tacrolimus, and mycophenolate mofetil) is given after the transplant to prevent graft-versus-host disease, a serious complication where donor cells attack the patient's body. The study aims to see if this approach reduces chronic graft-versus-host disease while still controlling the cancer. About 300 participants up to age 60 are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hematopoietic stem cell transplant (bone marrow or blood stem cells from a donor) followed by cyclophosphamide, tacrolimus, and mycophenolate mofetil
What this could lead to: If successful, this approach could improve survival and reduce severe side effects for people with blood cancers needing a stem cell transplant.
What could go wrong: This is a mid-stage trial, so results are not yet proven. Risks include graft failure, serious infections, and graft-versus-host disease, which can be life-threatening.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACQUIRED BONE MARROW FAILURE SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia acute lymphoblastic leukemia acute myeloid leukemia B-cell chronic lymphocytic leukemia Burkitt lymphoma chronic myelogenous leukemia, BCR-ABL1 positive diffuse large B-cell lymphoma follicular lymphoma juvenile myelomonocytic leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive lymphoblastic lymphoma lymphoma Lymphoma, B-Cell, Marginal Zone lymphoplasmacytic lymphoma mantle cell lymphoma marginal zone lymphoma myelodysplastic syndrome myelodysplastic syndrome with excess blasts myelodysplastic syndrome with single lineage dysplasia myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm plasma cell leukemia plasma cell myeloma Precursor Cell Lymphoblastic Leukemia-Lymphoma primary myelofibrosis prolymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACQUIRED BONE MARROW FAILURE SYNDROMES ACUTE LEUKEMIA ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE MYELOID LEUKEMIA BIPHENOTYPIC/UNDIFFERENTIATED/PROLYMPHOCYTIC LEUKEMIAS BURKITT LYMPHOMA CHRONIC LYMPHOCYTIC LEUKEMIA CHRONIC MYELOGENOUS LEUKEMIA DIFFUSE LARGE CELL NON HODGKINS LYMPHOMA FOLLICULAR LYMPHOMA HIGH GRADE NON-HODGKIN'S LYMPHOMA, ADULT HIGH RISK ANEMIA JUVENILE MYELOMONOCYTIC LEUKEMIA LYMPHOBLASTIC LYMPHOMA LYMPHOMA LYMPHOPLASMACYTIC LYMPHOMA MANTLE CELL LYMPHOMA MARGINAL ZONE B CELL LYMPHOMA MRD POSITIVE LEUKEMIA MULTIPLE MYELOMA MYELODYSPLASIA MYELOFIBROSIS MYELOPROLIFERATIVE NEOPLASMS NATURAL KILLER CELL MALIGNANCIES PLASMA CELL LEUKEMIA PROLYMPHOCYTIC LEUKEMIA REFRACTORY ANEMIA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

Masonic Cancer Center at University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55337, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.